BioSpace News Archive

No recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p =0.0338)

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that it has launched an offering of a combined $1.75 billion aggregate principal amount of new senior notes due 2029 (the “2029 Notes”) and new senior notes due 2031 (the “2031 Notes” and, together with the 2029 Notes, the “Notes”).

QBiotics Group Limited (QBiotics), a life sciences company developing novel anticancer and wound healing pharmaceuticals, is delighted to announce that the U.S. Food and Drug Administration’s (U.S. FDA) Center for Veterinary Medicine (CVM) has approved its lead veterinary anticancer product, STELFONTA, making it the first FDA approved treatment for all grades of canine non-metastatic mast cell tumours.

Syneos Health, Inc., the only fully integrated biopharmaceutical solutions organization combining a CRO and a CCO, announced it commenced an offering of $500.0 million aggregate principal amount of senior notes in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), and BayMedica Inc

The Phase number of the clinical trial in the first paragraph, first sentence of release should read: Phase I/II (instead of Phase I/I). The updated release reads: ORGANICELL ANNOUNCES ADDITIONAL SITE FOR PHASE I/II CLINICAL TRIAL OF ZOFIN™ FOR TREATMENT OF COVID-19

Today, ixlayer, a leader in technology-based solutions for healthcare management, announced a new platform to optimize and accelerate the highly-complex process of distributing COVID-19 vaccines while managing the response to the virus

Ultivue and Indivumed today announced that the two companies have entered into a collaborative partnership to further accelerate research and drug development in the area of personalized oncology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005281/en/ The deal links Indivumed’s vast array of standardized and fully c

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will be presenting at the Sidoti & Company Virtual Microcap Conference on Thursday, November 19, 2020 at 1:45 p.m. Eastern Time. The presentation will be webcast live and av